BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1523100)

  • 1. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.
    Sultan Y; Loyer F; Venot A
    Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
    Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
    Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease.
    Wieczorek I; Ludlam CA; MacGregor IR
    Blood Coagul Fibrinolysis; 1994 Jun; 5(3):329-34. PubMed ID: 8075304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood fibrinolysis and the response to desmopressin in glomerulonephritis.
    Brommer EJ; Van den Wall Bake AW; Dooijewaard G; van Loon BJ; Emeis JJ; Weening JJ
    Thromb Haemost; 1994 Jan; 71(1):19-25. PubMed ID: 8165642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects.
    MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P
    Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
    Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
    Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand's disease with low platelet von Willebrand factor content.
    Casonato A; Sartori MT; Pontara E; Zucchetto A; Dannhäuser D; Patrassi G; Girolami A
    Blood Coagul Fibrinolysis; 1992 Apr; 3(2):149-53. PubMed ID: 1606286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities.
    Moffat EH; Giddings JC; Bloom AL
    Br J Haematol; 1984 Aug; 57(4):651-62. PubMed ID: 6430337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
    Pedersen OD; Gram J; Jespersen J
    Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
    Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
    Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease.
    Ludlam CA; Peake IR; Allen N; Davies BL; Furlong RA; Bloom AL
    Br J Haematol; 1980 Jul; 45(3):499-511. PubMed ID: 6775673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion.
    Keber D; Stegnar M; Kluft C
    Thromb Haemost; 1990 Feb; 63(1):72-5. PubMed ID: 2111049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies.
    van de Kar NC; van Hinsbergh VW; Brommer EJ; Monnens LA
    Pediatr Res; 1994 Aug; 36(2):257-64. PubMed ID: 7970942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states.
    Niwano H; Takahashi H; Tatewaki W; Wada K; Seki Y; Shibata A
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):389-93. PubMed ID: 1420814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism.
    Levesque H; Borg JY; Cailleux N; Vasse M; Daliphard S; Gancel A; Monconduit M; Courtois H
    Eur J Med; 1993 May; 2(5):287-8. PubMed ID: 8252160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.